Omeros is advancing two of its product candidates from its PharmacoSurgery platform: OMS103HP for arthroscopic meniscectomy and OMS302 for intra-ocular lens replacement surgery; both candidates are going into phase III clinical development programs.  Additionally, the candidates have been added to standard irrigation solutions and delivered intra-operatively to the operative site throughout the surgical procedure to preemptively block the molecular-signaling and biochemical cascade caused by surgical trauma and to provide clinical benefits both during and after surgery.

The OMS103HP phase 3 clinical program will evaluate the drug's safety and efficacy in improving postoperative joint function and reducing pain following arthroscopic partial meniscectomy surgery. The program will consist of two randomized, double-blind, vehicle-controlled, multicenter trials to be conducted in North America and Europe.

OMS302 will be evaluated for safety and efficacy in patients undergoing intra-ocular lens replacement surgery. The trials, conducted in North America and Europe, will enroll both cataract surgery and refractive lens exchange patients. This clinical program will involve two randomized, double-blind, placebo-controlled, multicenter trials.